Loading...

Apexigen, Inc.

APGN•NASDAQ
Healthcare
Biotechnology
$0.39
$0.03(8.48%)

Apexigen, Inc. (APGN) Stock Overview

Explore Apexigen, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 64.3/100

Key Financials

Market Cap9.6M
P/E Ratio-0.24
EPS (TTM)$-1.71
ROE0.48%

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$0.20

APGN Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Apexigen, Inc. (APGN) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.20.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.24 and a market capitalization of 9.6M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for APGNStats details for APGN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for APGNAnalyst Recommendations details for APGN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Apexigen Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and rectal and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. The company was founded in 2010 and is based in San Carlos, California.

CEO

Dr. Xiaodong Yang M.D., Ph.D.

Employees

11

Headquarters

75 Shoreway Road, San Carlos, CA

Founded

2021

Frequently Asked Questions

;